XML 53 R43.htm IDEA: XBRL DOCUMENT v3.22.2
Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Schedule of Acquisitions and Cost-Reduction/Productivity Initiatives (Detail) - USD ($)
$ in Millions
3 Months Ended 6 Months Ended
Mar. 11, 2022
Jul. 03, 2022
Apr. 03, 2022
Jul. 04, 2021
Jul. 03, 2022
Jul. 04, 2021
Restructuring charges/(credits):            
Employee terminations   $ 110   $ (4) $ 135 $ 19
Asset impairments   20   2 28 (3)
Exit costs/(credits)   18   (3) 29 (3)
Restructuring charges/(credits) [1]   147   (5) 191 12
Transaction costs [2]   36   0 42 0
Integration costs and other [3]   6   4 148 8
Restructuring charges and certain acquisition-related costs   189   (1) 381 21
Additional depreciation––asset restructuring [4]   7   43 15 49
Implementation costs [5]   149   90 235 166
Total costs associated with acquisitions and cost-reduction/productivity initiatives   345   137 625 248
Biopharma [Member]            
Restructuring charges/(credits):            
Restructuring charges/(credits)   50   (4) 46 1
Other (income)/deductions––net [Member]            
Restructuring charges/(credits):            
Net periodic benefit costs/(credits) recorded in Other (income)/deductions––net   0   4 (6) 12
Cost of sales [Member]            
Restructuring charges/(credits):            
Additional depreciation––asset restructuring [4]   7   27 15 34
Implementation costs [5]   15   10 27 21
Selling, informational and administrative expenses [Member]            
Restructuring charges/(credits):            
Additional depreciation––asset restructuring [4]   0   16 0 16
Implementation costs [5]   $ 134   $ 80 $ 208 $ 144
Restructuring Charges And Acquisition-Related Costs [Member] | Arena [Member]            
Restructuring charges/(credits):            
Post closing compensation expense $ 138   $ 138      
[1] Primarily represents cost reduction initiatives. Restructuring charges/(credits) associated with Biopharma: charges of $50 million and $46 million for the three and six months ended July 3, 2022, respectively, and credits of $4 million and charges of $1 million for the three and six months ended July 4, 2021, respectively.
[2] Represents external costs for banking, legal, accounting and other similar services.
[3] Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In the three and six months ended July 3, 2022, integration costs and other were mostly related to our acquisition of Arena, including $138 million in payments to Arena employees in the first quarter of 2022 for the fair value of previously unvested long-term incentive awards. See Note 2A.
[4] Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
[5] Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.